Adult Cardiothoracic Surgery »  Meet the Team »  Tobias Deuse, M.D.

Tobias Deuse, M.D.

Associate Professor of Surgery
Division of Adult Cardiothoracic Surgery
Director, Minimally Invasive Cardiac Surgery



Contact Information

Academic Office
500 Parnassus Ave., MUW-405
San Francisco, CA 94143-0118
(415) 353 8890
Tobias.Deuse@ucsf.edu

Open Popup
  • University of Stuttgart (Germany), BS, Physics, 1994
  • University of Leipzig (Germany) Medical School, 1995
  • Julius-Maximilian-University Würzburg (Germany) Medical School, MD, 2000
  • Ludwig-Maximilian-University Munich (Germany) Medical School, 2001
  • University Hospital Munich-Grosshadern (Germany), Cardiac Surgery, 2001
  • University Heart Center Hamburg-Eppendorf (Germany), Cardiovascular Surgery, 2002-2007
  • Stanford University, Lung and Heart-Lung Transplantation, Fellowship Program, 2007-2009
  • UCSF Heart & Vascular Center
  • Oxidative Stress and Apoptosis
  • Pulmonary Hypertension
  • Stem Cell Immunobiology
  • Transplant Immunology
  • Vascular Biology
  • German

Tobias Deuse, M.D. is a cardiac and heart transplant surgeon internationally renowned for his pioneering work in the development of minimally-invasive techniques for mitral valve repair. 

Dr. Deuse graduated the University of Stuttgart (Germany) in 1994 with a BS in Physics, and in 2000 earned an M.D. from University of Wuerzburg. Dr. Deuse thereafter received advanced training in cardiothoracic surgery at the University Hospital Munich-Grosshadern and University Heart Center Hamburg-Eppendorf. After obtaining his board certification in Germany in 2007 as a heart surgeon, Dr. Deuse completed a surgical fellowship in Lung and Heart-Lung Transplantation at Stanford.

After returning to Germany in 2009, Dr. Deuse was appointed Director for Heart and Lung Transplantation at the University Heart Center in Hamburg. He achieved international acclaim for his development of innovative approaches to heart failure surgery, most notably minimally-invasive techniques for the implantation of ventricular assist systems. 

Dr. Deuse also demonstrated that high success rates could be achieved in mitral valve repair utilizing robotic-assisted (fully) endoscopic surgery. This minimally invasive procedure, also known as "keyhole surgery", has numerous benefits for the patient including substantially reduced post-surgical pain, shorter hospital stays, and a faster recovery and return to normal activities. 

Dr. Deuse has also been the recipient of numerous honors including election to the Board of Directors of the International Society for Heart and Lung Transplantation (ISHLT).

Dr. Deuse's research is focused on vascular biology and pathophysiology. His group was the among the first to elucdiate the novel pathways involved in the development of vascular intimal hyperplasia. Myointimal hyperplasia is a pathological process of the vascular system characterized by abnormal proliferation of smooth muscle cells of the vascular wall that leads to luminal obliteration and subsequent ischemia.

Myointimal hyperplasia may occur in patients after vessel injury during medical procedures (e.g. after balloon dilation or stent placement) or after pathological injury of the blood vessel (e.g. due to inflammation or toxic exposure). It can cause bypass graft failure and in-stent restenosis. To help prevent this and increase the success of treatments for vascular disease including coronary heart disease, his research group is working on the development of new preventive drug regimes and strategies.

Most recent publications from a total of 100
  1. Guihaire J, Itagaki R, Stubbendorff M, Hua X, Deuse T, Ullrich S, Fadel E, Dorfmüller P, Robbins RC, Reichenspurner H, Schumacher U, Schrepfer S. Orthotopic tracheal transplantation using human bronchus: an original xenotransplant model of obliterative airway disorder. Transpl Int. 2016 Sep 10. View in PubMed
  2. Westhofen S, Kugler C, Reichenspurner H, Deuse T. Acute Pulmonary Artery Obstruction as the Primary Manifestation of a Rapidly Growing Intimal Sarcoma in a 54-Year-Old Patient. Thorac Cardiovasc Surg Rep. 2016 Dec; 5(1):36-38. View in PubMed
  3. Westhofen S, Conradi L, Deuse T, Detter C, Vettorazzi E, Treede H, Reichenspurner H. A matched pairs analysis of non-rib-spreading, fully endoscopic, mini-incision technique versus conventional mini-thoracotomy for mitral valve repair. Eur J Cardiothorac Surg. 2016 Dec; 50(6):1181-1187. View in PubMed
  4. Deuse T, Hua X, Stubbendorff M, Spin JM, Neofytou E, Taylor V, Chen Y, Park G, Fink JB, Renne T, Kiefmann M, Kiefmann R, Reichenspurner H, Robbins RC, Schrepfer S. The Selective JAK1/3-Inhibitor R507 Mitigates Obliterative Airway Disease Both With Systemic Administration and Aerosol Inhalation. Transplantation. 2016 May; 100(5):1022-31. View in PubMed
  5. Deuse T, Bara C, Barten MJ, Hirt SW, Doesch AO, Knosalla C, Grinninger C, Stypmann J, Garbade J, Wimmer P, May C, Porstner M, Schulz U. The MANDELA study: A multicenter, randomized, open-label, parallel group trial to refine the use of everolimus after heart transplantation. Contemp Clin Trials. 2015 Nov; 45(Pt B):356-63. View in PubMed
  6. Guihaire J, Deuse T, Wang D, Fadel E, Reichenspurner H, Schrepfer S. Sex Differences in Immunology: More Severe Development of Experimental Pulmonary Hypertension in Male Rats Exposed to Vascular Endothelial Growth Factor Receptor Blockade. Biomed Res Int. 2015; 2015:765292. View in PubMed
  7. Deuse T, Schrepfer S. Distal Airway Stem Cells are Essential for Lung Regeneration. Transplantation. 2015 Aug; 99(8):1540-1. View in PubMed
  8. Wang D, Deuse T, Stubbendorff M, Chernogubova E, Erben RG, Eken SM, Jin H, Li Y, Busch A, Heeger CH, Behnisch B, Reichenspurner H, Robbins RC, Spin JM, Tsao PS, Schrepfer S, Maegdefessel L. Local MicroRNA Modulation Using a Novel Anti-miR-21-Eluting Stent Effectively Prevents Experimental In-Stent Restenosis. Arterioscler Thromb Vasc Biol. 2015 Sep; 35(9):1945-53. View in PubMed
  9. Neofytou E, Deuse T, Beygui RE, Schrepfer S. Mesenchymal stromal cell therapy: different sources exhibit different immunobiological properties. Transplantation. 2015 Jun; 99(6):1113-8. View in PubMed
  10. Conradi L, Schmidt S, Neofytou E, Deuse T, Peters L, Eder A, Hua X, Hansen A, Robbins RC, Beygui RE, Reichenspurner H, Eschenhagen T, Schrepfer S. Immunobiology of fibrin-based engineered heart tissue. Stem Cells Transl Med. 2015 Jun; 4(6):625-31. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Tobias Deuse, M.D.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

X